MedPath

Efficacy and Safety Study of Saxagliptin + Metformin Immediate Release (IR) Versus Metformin IR Alone in Type 2 Diabetes Mellitus

Phase 3
Completed
Conditions
Type 2 Diabetes Mellitus
Interventions
Drug: Placebo plus metformin IR
Registration Number
NCT00885378
Lead Sponsor
AstraZeneca
Brief Summary

The purpose of this study is to compare the reduction in hemoglobin A1C (A1C) for participants taking saxagliptin in combination with metformin immediate release (IR) versus metformin IR alone.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
166
Inclusion Criteria
  • Type 2 diabetes
  • 18-78 years of age
  • Taking stable twice daily (BID) dosing of metformin IR (at least 1500 mg) for at least 8 weeks
  • A1C: 7-10%
  • C-peptide: ≥ 0.8 ng/mL
  • Body mass index (BMI): ≤45 kg/m^2
Exclusion Criteria
  • Women of childbearing potential unable or unwilling to use acceptable birth control
  • Women who are pregnant or breastfeeding
  • Fasting plasma glucose (FPG) >270 mg/dL
  • Significant cardiovascular history
  • Symptoms of poorly controlled diabetes
  • History of diabetic ketoacidosis or hyperosmolar nonketotic coma
  • Insulin therapy within one year of screening
  • Cardiovascular even within the prior 6 months
  • New York Heart Association Stage III/IV congestive heart failure and/or known left ventricular ejection fraction <=40%
  • Significant history of renal or hepatic disease
  • History of a psychiatric disorder, alcohol or drug abuse within the previous year
  • Treatment with potent CYP3A4 inhibitors or inducers
  • Immunocompromised participants
  • Active liver disease or clinically significant abnormal hepatic, renal , endocrine, metabolic, or hematological screening tests

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Saxagliptin plus metformin IRSaxagliptin plus metformin IR-
Placebo plus metformin IRPlacebo plus metformin IR-
Primary Outcome Measures
NameTimeMethod
Mean Hemoglobin A1C (A1c) and Change From Baseline to Week 12Baseline, Week 12

Mean change was adjusted for baseline.

Secondary Outcome Measures
NameTimeMethod
Mean Baseline and Change From Baseline in Fasting Plasma Glucose (FPG)Baseline, Week 12

Mean change was adjusted for baseline.

Percentage of Participants Achieving a Therapeutic Glycemic Response (A1C < 7.0%) at Week 12Week 12

Adjusted for baseline. Calculated using the method by Zhang et al. (Zhang M, Tsiatis A, Davidian M. Improving efficiency of inference in randomized clinical trials using auxiliary covariates. Biometrics. Published online on January 11, 2008; Digital Object Identifier: 10.1111/j.1541-0420.2007.00976.x.)

Percentage of Participants Achieving a Therapeutic Glycemic Response (A1C <= 6.5%) at Week 12Week 12

Adjusted for baseline. Calculated using the method by Zhang et al. (Zhang M, Tsiatis A, Davidian M. Improving efficiency of inference in randomized clinical trials using auxiliary covariates. Biometrics. Published online on January 11, 2008; Digital Object Identifier: 10.1111/j.1541-0420.2007.00976.x.)

Trial Locations

Locations (26)

John Muir Physician Network Clinical Research Center

🇺🇸

Concord, California, United States

Wells Institute For Health Awareness

🇺🇸

Kettering, Ohio, United States

Newark Physician Associates

🇺🇸

Newark, Ohio, United States

Southland Clinical Research Center, Inc.

🇺🇸

Fountain Valley, California, United States

Ritchken & First M.D.'S

🇺🇸

San Diego, California, United States

Community Health Care Of Manchester

🇺🇸

Akron, Ohio, United States

Jolene K. Berg, Md., Dgd Research, Inc.

🇺🇸

San Antonio, Texas, United States

Tidewater Integrated Medical Research

🇺🇸

Virginia Beach, Virginia, United States

Southeastern Research Associates, Inc

🇺🇸

Taylors, South Carolina, United States

Central Florida Clinical Trials, Inc.

🇺🇸

Altamonte Springs, Florida, United States

Family Care Associates Of Nw Florida

🇺🇸

Chipley, Florida, United States

Nextphase Clinical Trials, Inc.

🇺🇸

Miami, Florida, United States

Middle Georgia Drug Study Center, Llc

🇺🇸

Perry, Georgia, United States

Louisiana Heart Center Research

🇺🇸

Slidell, Louisiana, United States

Jackson Clinic

🇺🇸

Rolling Fork, Mississippi, United States

Midwest Regional Research, Inc.

🇺🇸

Bellbrook, Ohio, United States

Integris Family Care South

🇺🇸

Oklahoma, Oklahoma, United States

Holston Medical Group

🇺🇸

Kingsport, Tennessee, United States

Integris Family Care Yukon

🇺🇸

Yukon, Oklahoma, United States

Williamette Valley Clinical Studies

🇺🇸

Eugene, Oregon, United States

Village Family Practice

🇺🇸

Houston, Texas, United States

Southwest Clinical Research Centers, Llc

🇺🇸

Pearland, Texas, United States

Local Institution

🇵🇷

San Juan, Puerto Rico

Torrance Clinical Research

🇺🇸

Lomita, California, United States

Clinical Therapeutics Corporation

🇺🇸

Coral Gables, Florida, United States

Integrated Medical Group Pc/Fleetwood Clinical Research

🇺🇸

Fleetwood, Pennsylvania, United States

© Copyright 2025. All Rights Reserved by MedPath